Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced that it will provide student conference sponsorship for a second year to the Future of Hearing Healthcare Conference, which will allow up to 75 audiology graduate students to attend the event at no cost.
New research led by investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear indicates that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2 (NF2), a hereditary condition associated with vestibular schwannomas, or noncancerous tumors along the nerves in the brain that are involved with hearing and balance.
Envoy Medical Corporation, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, announced an independent study that was published online in 'The Journal of Laryngology & Otology.' The study found that the fully implanted Esteem osseointegrated active middle ear implant (AMEI) showed “statistically significant improvements in post-operative hearing results,” according to Envoy.
The normal audition was reported to play a keen role in effective communication by the construction of motor plans. This was observed to be an outcome of auditory feedback of one’s own speech.
Read More
The researchers concluded that “SARS‐CoV‐2 is a probable cause of middle ear infections and sensorineural hearing loss, secondary to spread of the novel virus into the middle ear and related neural structures.”
Read More
NYU Langone clinicians combined local anesthesia and conscious sedation (LA-CS) in cochlear implantation for the first time in 2006. The team has regularly performed the procedure ever since, establishing a mounting body of evidence of the approach’s efficacy and safety.
Read More
The scientists administered bisphosphonates to mice 24 hours after noise exposure. They found that the medication had a dramatic effect at regenerating the synapses between inner hair cells and spiral ganglion neurons found in the ear, and restoring cochlear function.
Read More
The research and support in practice by trained hearing health professionals provided the foundation to approve the indication be lowered to 9 months, along with the considerable developments in technology and evolving speech coding strategies in modern day cochlear implant devices.
Read More
FX-322 is Frequency’s lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss (SNHL).
Read More
This approval “helps ensure children born deaf have earlier access to a cochlear implant which can provide them with the hearing capabilities to develop speech and language at a trajectory similar to their hearing peers.”
Read More
Sensorion (FR0012596468 – ALSEN) a clinical-stage biotech company which specializes in the...
Read More
CROS and BiCROS hearing aids are not the only treatment options for those with unilateral hearing loss. This article reviews other options and potential future avenues for unilateral sensorineural hearing loss and single-sided deafness, as well as for unilateral conductive hearing loss.
Read More
In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.
Read More
Douglas Beck & Virginia Ramachandran examine the various forms of unilateral hearing loss and review the various treatment methods with particular emphasis on the effectiveness of CROS and BiCROS hearing aid fittings.
Read More
AK-OTOF is intended to treat individuals with sensorineural hearing loss due to mutations in the OTOF gene, who typically have severe hearing loss in both ears from birth, by promoting the expression of normal, functional otoferlin protein in affected cells of the cochlea.
Read More
This study suggests that not properly treating infections or other conditions that chronically affect the middle ear may lead to neural deficits and increased difficulties hearing in noisy environments.
Read More
Sudden sensorineural hearing loss (SSNHL) affects five to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States, according to the organization.
Read More
This is reportedly “the first and only time” that cochlear implants have been approved for these indications in the United States.
Read More